AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
01/24/2023 - 04:05 PM
VANCOUVER, British Columbia --(BUSINESS WIRE)--
AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023 , and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time ) the same day.
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com .
Source: AbCellera Biologics Inc.
View source version on businesswire.com : https://www.businesswire.com/news/home/20230123005747/en/
Inquiries
Jessica Yingling , Ph.D.; media@abcellera.com , +1(236)521-6774
Murray McCutcheon , Ph.D.; bd@abcellera.com , +1(604)559-9005
ir@abcellera.com , +1(778)729-9116
Source: AbCellera Biologics Inc.
ABCL Rankings
#5068 Ranked by Stock Gains
ABCL Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Country
CA
City
Vancouver
About ABCL
abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’
